Elevated Serum Levels of Soluble CD30 in Ankylosing Spondylitis Patients and Its Association with Disease Severity-Related Parameters

Gao, Rongfen; Sun, Wei; Chen, Yu; Su, Yuying; Wang, Chenqiong; Dong, Lingli

doi:10.1155/2015/617282

Cited by 7 publications

(5 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There are scarce data on the effect of ART on sCD30 [ 26 ]. Levels in our population were considerably lower than those measured in the first 4 weeks of ART [ 48 ], and closer to levels published from HIV-negative volunteers [ 28 ]; however, sCD30 showed no independent association with virologic parameters. Levels of sCD14, IL-6, and cellular markers of immune activation in our study population were comparable to those previously measured in HIV-1-positive patients receiving ART for up to 6 years [ 19 , 49 ].…”

Section: Discussionsupporting

confidence: 74%

Factors Associated With Persistence of Plasma HIV-1 RNA During Long-term Continuously Suppressive Firstline Antiretroviral Therapy

Ruggiero

Cozzi‐Lepri

Beloukas

et al. 2018

Open Forum Infectious Diseases

View full text Add to dashboard Cite

BackgroundPersistence of plasma HIV-1 RNA during seemingly effective antiretroviral thereapy (ART) is incompletely understood. Using an ultrasensitive assay, this cross-sectional study investigated residual plasma HIV-1 RNA in subjects maintained on firstline ART with continuous viral load suppression <50 copies/mL for ≤15 years without recognized viral load blips or treatment interruptions and explored its relationship with the duration of suppressive ART, efavirenz concentrations in plasma, 2-LTR circular HIV-1 DNA (2-LTRc DNA) in peripheral blood mononuclear cells, and cellular (CD4 plus CD26/CD38/CD69; CD8 plus CD38/HLA-DR/DP/DQ) and soluble (sCD14, sCD27, sCD30, IL-6) markers of immune activation in peripheral blood. MethodsResidual plasma HIV-1 RNA, total HIV-1 DNA and 2-LTRc DNA were quantified by real-time and digital droplet PCR. Cellular (CD4 plus CD26/CD38/CD69; CD8 plus CD38/HLA-DR/DP/DQ) and soluble (sCD14, sCD27, sCD30, IL-6) markers of immune activation were measured by flow cytometry and ELISA.ResultsResidual plasma HIV-1 RNA and 2-LTRc DNA were detected in 52/104 (50%) and 24/104 (23%) subjects, respectively. Among subjects with detectable HIV-1 RNA, 50/52 showed levels ≤11 copies/mL. In adjusted analyses, HIV-1 RNA levels were 0.37 log10 copies/mL higher with each log10 U/mL increase in sCD27 (95% confidence interval, 0.01–0.73; P = .02). No significant association was found between residual plasma HIV-1 RNA and other explored parameters. ConclusionsThese findings point to an ongoing relationship between plasma HIV-1 RNA and selected markers of immune activation during continuously suppressive ART. The novel direct association with levels of sCD27 warrants further investigation.

show abstract

Section: Discussionsupporting

confidence: 74%

Factors Associated With Persistence of Plasma HIV-1 RNA During Long-term Continuously Suppressive Firstline Antiretroviral Therapy

Ruggiero

Cozzi‐Lepri

Beloukas

et al. 2018

Open Forum Infectious Diseases

View full text Add to dashboard Cite

show abstract

“…We here identified a large number (40) of genes that have well-documented roles in the immune response, including for example TNFSF8/CD30L, interleukin-32 and several Th17-lymphocytes-related genes. TNFSF8 is a TNF-family member expressed on activated peripheral blood T-cells, B-cells, neutrophils, mast cells, monocytes, and macrophages and it is the ligand for CD30, a molecule that is present at high levels in AS patients compared to healthy controls [ 25 ]. The CD30/CD30L signaling system has been implicated in the pathogenesis of several autoimmune and inflammatory diseases and it has been recently associated to the pathogenesis of rheumatoid arthritis synovitis [ 26 ].…”

Section: Discussionmentioning

confidence: 99%

Gene Expression Analysis before and after Treatment with Adalimumab in Patients with Ankylosing Spondylitis Identifies Molecular Pathways Associated with Response to Therapy

Dolcino

Tinazzi

Pelosi

et al. 2017

Genes

View full text Add to dashboard Cite

The etiology of Ankylosing spondylitis (AS) is still unknown and the identification of the involved molecular pathogenetic pathways is a current challenge in the study of the disease. Adalimumab (ADA), an anti-tumor necrosis factor (TNF)-alpha agent, is used in the treatment of AS. We aimed at identifying pathogenetic pathways modified by ADA in patients with a good response to the treatment. Gene expression analysis of Peripheral Blood Cells (PBC) from six responders and four not responder patients was performed before and after treatment. Differentially expressed genes (DEGs) were submitted to functional enrichment analysis and network analysis, followed by modules selection. Most of the DEGs were involved in signaling pathways and in immune response. We identified three modules that were mostly impacted by ADA therapy and included genes involved in mitogen activated protein (MAP) kinase, wingless related integration site (Wnt), fibroblast growth factor (FGF) receptor, and Toll-like receptor (TCR) signaling. A separate analysis showed that a higher percentage of DEGs was modified by ADA in responders (44%) compared to non-responders (12%). Moreover, only in the responder group, TNF, Wnt, TLRs and type I interferon signaling were corrected by the treatment. We hypothesize that these pathways are strongly associated to AS pathogenesis and that they might be considered as possible targets of new drugs in the treatment of AS.

show abstract

“…The relatively high level of sCD30, whether statistically significant or not, in non-responders in our study may be related to this effect of biologic drugs. Disease-related factors could affect the level of sCD30; Gao et al reported that sCD30 level was significantly higher in AS [29] . Duzgun et al have reported the correlation between sCD30 and Behçet disease [30] .…”

Section: Discussionmentioning

confidence: 99%

The Association Between Vaccine Response and sCD30 Level in Patients Using Immunomodulator Drugs and Having Received Hepatitis B Vaccination

Solay¹,

Gültuna²,

Tayşi³

2020

FLORA

View full text Add to dashboard Cite

Introduction: Biologic agents like adalimumab, infliximab, etanercept, ustekunimab and golimumab used for autoimmune diseases suppress T cell-mediated immune response. The defects of cytokines related to T helper 1 and 2 cells have been detected in non-responder subjects to hepatitis B virus (HBV) vaccine. Soluble Cluster of Differentiation 30 (sCD30) is related to the balance of T helper 1/2. Therefore, we investigated the impact of sCD30 on vaccine response. To our knowledge, this is the first study to evaluate the role of sCD30 as a potential serological marker of HBV vaccine response. Materials and Methods:Seventy-five patients using biologic drugs were vaccinated with hepatitis B vaccine at a dosage of 20 or 40 µg. The serum titer of anti-HBs and sCD30 were measured four weeks after the last vaccine dose.Results: Thirty-nine (52%) of the participants were male. Mean age was 43.4 ± 11.5 years. Forty-one (54.7%) patients received standard dose HBV vaccine. Thirty-eight (50.7%) patients responded. Serum sCD30 level was similar in responders and non-responders to HBV vaccine in the whole group. However, we found an inverse relation between antibody response to HBV vaccine and sCD30 level in patients with psoriasis who received high dose vaccine regime [69.5 (28.5-131.7) pg/mL and 47.1 (32.0-80.6) pg/mL respectively, p= 0.037]. Conclusion:This study pointed out that sCD30 may play a role in hepatitis B vaccine response. Giriş: Otoimmün hastalıklarda kullanılan adalimumab, infliksimab, etanersept, ustekunimab ve golimumab gibi biyolojik ajanlar T hücre aracılı immün yanıtı baskılar. T helper 1 ve 2 ile ilişkili sitokin salınımında gelişen sorun, hepatit B virüsü (HBV) aşısına yanıtsızlıkla sonuçlanmaktadır. sCD30 T helper ½ dengesi ile ilişkilidir. Bu nedenle bu çalışmada, sCD30'un aşı yanıtı üzerindeki etkisini incelemek amaçlanmıştır. Bu çalışma bildiğimiz kadarıyla, sCD30'un HBV aşı yanıtındaki rolünü değerlendiren ilk çalışmadır. Materyal ve Metod: Biyolojik ilaç kullanan ve 20 veya 40 µg dozda hepatit B aşısı yapılan 75 hasta çalışmaya dahil edildi. Son aşıdan dört hafta sonra anti-HBs ve sCD30'un serum titresi ölçüldü. Bulgular: Hastaların 39 (%52)'u erkektir ve ortalama yaşları 43.4 ± 11.5 yıl olarak bulunmuştur. Kırk bir (%54.7) hastaya standart doz HBV aşısı yapılmıştır. Otuz sekiz (%50.7) hastanın aşı yanıtı vardı. Serum sCD30 düzeyi, HBV aşı yanıtı olan ve olmayan gruplarda benzerdi. Fakat, yüksek doz aşı yapılan psöriyazisli hastalarda HBV aşısına karşı antikor yanıtı ile sCD30 düzeyi arasında ters ilişki [sırasıyla 69.5 (28.5-131.7) pg/mL ve 47.1 (32.0-80.6) pg/mL, p= 0.037] bulunmuştur. Sonuç: Bu çalışma sCD30'un hepatit B aşı yanıtında rol oynayabileceğini işaret etmektedir.Anahtar Kelimeler: Hepatit B aşısı; sCD30; T hücre; Yanıt

show abstract

Elevated Serum Levels of Soluble CD30 in Ankylosing Spondylitis Patients and Its Association with Disease Severity-Related Parameters

Cited by 7 publications

References 28 publications

Factors Associated With Persistence of Plasma HIV-1 RNA During Long-term Continuously Suppressive Firstline Antiretroviral Therapy

Factors Associated With Persistence of Plasma HIV-1 RNA During Long-term Continuously Suppressive Firstline Antiretroviral Therapy

Gene Expression Analysis before and after Treatment with Adalimumab in Patients with Ankylosing Spondylitis Identifies Molecular Pathways Associated with Response to Therapy

The Association Between Vaccine Response and sCD30 Level in Patients Using Immunomodulator Drugs and Having Received Hepatitis B Vaccination

Contact Info

Product

Resources

About